Kissei Pharmaceutical
As of the edition of 20 October 2026, Kissei Pharmaceutical runs 20 drugs, 10 of them marketed; it is on route A at 2 targets and on route B at 6 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 10 |
| Active | 3 |
| Went quiet | 5 |
| Stopped | 1 |
| Status not established | 1 |
| Total | 20 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Fostamatinib | Ends 2031 (patent) | 3 |
| Dexrazoxane | none listed | 5 |
| Ferric oxyhydroxide | Ends 2028 (exclusivity) | 0 |
| Avacopan | Ends 2039 (patent) | 1 |
| Difelikefalin | Ends 2032 (patent) | 2 |
| Linzagolix | none listed | 2 |
| Mitiglinide | none listed | 0 |
| Voglibose | none listed | 0 |
| Doxapram | none listed | 2 |
| Mitiglinide calcium dihydrate | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 2 targets, route B at 6 targets.
All 8 rows on route A or B
In the product8 company-target rows on route A or B; 5 are not shown here, and no score is.
See all 8 targets where Kissei Pharmaceutical needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nervous system: 13 trials led
- Urinary and reproductive: 13 trials led
- Pregnancy and women's health: 12 trials led